HBM Healthcare Investments

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines to address unmet medical needs. Its lead candidate, amezosvatein (also known as CRV-101), is an adjuvanted subunit vaccine designed to prevent shingles (herpes zoster) and chickenpox (varicella). The company focuses on improving vaccine efficacy, safety, and tolerability while advancing its pipeline through clinical trials.

Sphingotec GmbH is a biomarker company based in Brandenburg, Germany, founded in 2002. The company specializes in developing and marketing in vitro diagnostic solutions that utilize novel blood-based protein biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions, including acute heart failure, acute kidney injury, and circulatory shock. Sphingotec also produces microtiter plates, which are commonly used in analytical research and diagnostic testing laboratories. Its focus is on addressing critically underserved diagnostic needs in the field of acute care, with an emphasis on improving patient outcomes through innovative biomarker technologies.

Bluejay Therapeutics is a biopharmaceutical company dedicated to developing cures for infectious diseases, with a primary focus on chronic Hepatitis B. This condition poses a significant global health challenge, and the company aims to address the urgent need for effective treatments. Bluejay is advancing two innovative therapeutic approaches: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class oral small molecule inhibitors targeting HBsAg. These strategies are designed to reduce hepatitis B surface antigen levels and restore adaptive immunity, potentially leading to a functional cure for patients. Additionally, the company’s research encompasses therapeutic options for chronic Hepatitis D, further solidifying its commitment to improving immunity and recovery for individuals affected by serious viral and liver diseases.

Alumis is a clinical-stage biopharmaceutical company dedicated to developing precision medicines for autoimmune disorders. By leveraging a proprietary data analytics platform and biological insights, Alumis aims to transform the treatment landscape for patients suffering from these conditions. The company focuses on identifying and advancing therapeutics based on genetically validated targets, which enables the creation of targeted therapies that significantly improve patient outcomes. With a team of experts experienced in drug discovery and immunology, Alumis seeks to replace broad immunosuppression with more effective, targeted treatment options, ultimately enhancing the quality of life for individuals affected by autoimmune diseases.

Shape Memory Medical Inc, based in Santa Clara, California, is a medical device company focused on developing innovative therapeutic solutions for the peripheral vascular, cardiovascular, and neurovascular markets. Founded to commercialize cutting-edge medical devices that utilize Shape Memory Polymer (SMP) materials, the company has introduced the first FDA-cleared device employing this technology within the vascular sector. This advancement allows physicians to enhance patient care through improved treatment options. The team at Shape Memory Medical possesses significant expertise in SMP foam technology and the commercialization of medical devices, positioning the company as a leader in its field.

Farmalisto is an online retailer that sells a range of products and services to its clients. The platform’s range of products include haircare, dampeners, solar protection, healing, moisturizing, anti-aging, toothbrushes, toothpastes, mouth rinses, dental silks, dentures, protection, cereals, baby hygiene, baby milks, and diapers. Farmalisto was launched in 2013 by Jose Mora Hernandez, Stefan Krautwald, and Matthias Fehr and is based in Bogota and Mexico City. Websites: https://www.farmalisto.com.mx https://www.farmalisto.com.co

Valo Health is a technology company focused on transforming the drug discovery and development process through the integration of human and machine intelligence. By leveraging machine learning, cloud computing, and extensive data analysis, Valo Health's platform facilitates the identification of previously unknown connections between genetic markers and diseases. This human-centric approach supports clients in the healthcare sector in the development of treatments for various conditions, including oncology, neurodegenerative diseases, and cardiovascular issues. Through its innovative platform, Valo Health aims to accelerate the creation of impactful therapies.

Mahzi Therapeutics is a biotechnology company founded in 2020 and based in San Mateo, California. The company is dedicated to addressing under-served rare genetic neurodevelopmental disorders through biopharmaceutical research, development, and manufacturing. By focusing on these rare diseases, Mahzi Therapeutics aims to contribute to the healthcare industry's ability to provide effective treatments for patients with significant unmet medical needs.

1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, that aims to make healthcare more accessible, understandable, and affordable. Launched in 2015, it allows users to find detailed information about medicines prescribed by doctors and purchase them directly. The platform enables users to search for drugs based on ailments, classes, companies, and brands. Additionally, 1mg offers a service that helps consumers find the right healthcare professionals tailored to their needs. Its diagnostics service enhances transparency and cost-effectiveness in lab tests, empowering Indian consumers and caregivers to choose appropriate healthcare services at competitive prices.

Shape Memory Medical Inc, based in Santa Clara, California, is a medical device company focused on developing innovative therapeutic solutions for the peripheral vascular, cardiovascular, and neurovascular markets. Founded to commercialize cutting-edge medical devices that utilize Shape Memory Polymer (SMP) materials, the company has introduced the first FDA-cleared device employing this technology within the vascular sector. This advancement allows physicians to enhance patient care through improved treatment options. The team at Shape Memory Medical possesses significant expertise in SMP foam technology and the commercialization of medical devices, positioning the company as a leader in its field.

Sphingotec GmbH is a biomarker company based in Brandenburg, Germany, founded in 2002. The company specializes in developing and marketing in vitro diagnostic solutions that utilize novel blood-based protein biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions, including acute heart failure, acute kidney injury, and circulatory shock. Sphingotec also produces microtiter plates, which are commonly used in analytical research and diagnostic testing laboratories. Its focus is on addressing critically underserved diagnostic needs in the field of acute care, with an emphasis on improving patient outcomes through innovative biomarker technologies.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for the treatment of sepsis and related conditions. The company's lead product candidate, Adrecizumab, is a humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone that plays a critical role in maintaining vascular integrity. Adrenomed aims to rescue vascular integrity in critically ill patients facing limited treatment options, particularly those suffering from septic shock and acute heart failure. The company employs a unique approach that combines its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker for patient identification. Adrenomed has established a strong intellectual property position, holding granted patents in all major markets for its innovative therapies.

Dren Bio is a biotechnology company that specializes in protein engineering technologies designed to target and deplete pathogenic cells, protein aggregates, and other disease-causing agents. With a focus on hematologic neoplasms, solid cancers, autoimmune disorders, and diseases related to protein aggregation, the company aims to provide innovative solutions for healthcare professionals in their efforts to combat various serious diseases. Operating under a holding company model, Dren Bio develops multiple projects as standalone assets, seeking to create value through its diverse portfolio of biotechnology initiatives.

Mineralys Therapeutics is a biopharmaceutical company that provides hypertension treatment. They also bring a targeted approach to the management of hypertension.

Farmalisto is an online retailer that sells a range of products and services to its clients. The platform’s range of products include haircare, dampeners, solar protection, healing, moisturizing, anti-aging, toothbrushes, toothpastes, mouth rinses, dental silks, dentures, protection, cereals, baby hygiene, baby milks, and diapers. Farmalisto was launched in 2013 by Jose Mora Hernandez, Stefan Krautwald, and Matthias Fehr and is based in Bogota and Mexico City. Websites: https://www.farmalisto.com.mx https://www.farmalisto.com.co

Sphingotec GmbH is a biomarker company based in Brandenburg, Germany, founded in 2002. The company specializes in developing and marketing in vitro diagnostic solutions that utilize novel blood-based protein biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions, including acute heart failure, acute kidney injury, and circulatory shock. Sphingotec also produces microtiter plates, which are commonly used in analytical research and diagnostic testing laboratories. Its focus is on addressing critically underserved diagnostic needs in the field of acute care, with an emphasis on improving patient outcomes through innovative biomarker technologies.

Neuron23, Inc. is a biotechnology company focused on developing therapies for genetic disorders, particularly neurological diseases such as Parkinson's and Alzheimer's. Founded in 2018 and headquartered in South San Francisco, California, with an additional office in Munich, Germany, the company utilizes advanced artificial intelligence and genetic insights to enhance drug discovery. Neuron23's innovative platform integrates the latest advancements in human genetics with AI-driven methodologies to create targeted treatments for patients facing debilitating health challenges. By focusing on genetically defined conditions, Neuron23 aims to improve therapeutic options and outcomes for individuals affected by these disorders.

Aculys Pharma is a pharmaceutical company that develops drugs and innovative medical treatments for neurological and psychiatric disorders.

1000Farmacie is a prominent pharmacy marketplace in Italy that operates an online shopping platform dedicated to providing a diverse selection of pharmaceutical products. By collaborating with a network of independent pharmacies, the company ensures that customers can purchase healthcare items at competitive prices. The platform offers the convenience of same-day delivery to specified locations, enabling users to save both time and money while accessing essential health products.

Mineralys Therapeutics is a biopharmaceutical company that provides hypertension treatment. They also bring a targeted approach to the management of hypertension.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for the treatment of sepsis and related conditions. The company's lead product candidate, Adrecizumab, is a humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone that plays a critical role in maintaining vascular integrity. Adrenomed aims to rescue vascular integrity in critically ill patients facing limited treatment options, particularly those suffering from septic shock and acute heart failure. The company employs a unique approach that combines its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker for patient identification. Adrenomed has established a strong intellectual property position, holding granted patents in all major markets for its innovative therapies.

Swixx Biopharma fully represents biopharma companies in the CEE. It is designed to fully replace biopharma, OTC, and medical device multinationals’ subsidiaries or business units in those countries, or therapeutic areas of CEE, that the multinational chooses not to enter, or to exit. The company was founded in 2014 and is registered in Baar, Switzerland. It has 100%-owned affiliates in Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Greece, Hungary, Kosovo, Latvia, Lithuania, North Macedonia, Montenegro, Poland, Romania, Russia, Serbia, Slovakia, and Slovenia.

SK biopharmaceuticals aims to become a top tier specialty pharmaceutical company with global new drugs & innovative pipeline in CNS / metabolic disorders and to provide world class specialized pharmaceutical manufacturing services.

Dren Bio is a biotechnology company that specializes in protein engineering technologies designed to target and deplete pathogenic cells, protein aggregates, and other disease-causing agents. With a focus on hematologic neoplasms, solid cancers, autoimmune disorders, and diseases related to protein aggregation, the company aims to provide innovative solutions for healthcare professionals in their efforts to combat various serious diseases. Operating under a holding company model, Dren Bio develops multiple projects as standalone assets, seeking to create value through its diverse portfolio of biotechnology initiatives.

Mahzi Therapeutics is a biotechnology company founded in 2020 and based in San Mateo, California. The company is dedicated to addressing under-served rare genetic neurodevelopmental disorders through biopharmaceutical research, development, and manufacturing. By focusing on these rare diseases, Mahzi Therapeutics aims to contribute to the healthcare industry's ability to provide effective treatments for patients with significant unmet medical needs.

IO Biotech is a clinical-stage biopharmaceutical company focused on developing innovative immune therapies for cancer treatment. Utilizing its proprietary T-win technology platform, the company creates immune-modulating cancer vaccines that activate T cells specifically targeting immune-suppressive molecules. This approach aims to induce the immune system to disrupt multiple pathways responsible for tumor-induced immunosuppression. IO Biotech has a solid track record in advancing both preclinical and clinical compounds, with its two lead candidates targeting IDO and PD-L1 currently in clinical development, while several additional therapies remain in the preclinical stage.

BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing specific and selective antibody-based therapeutics for various cancers. The company employs a proprietary platform to create conditionally active biologics (CABs), which enhance targeting of cancerous tissues while minimizing effects on normal cells, thereby improving safety and efficacy. BioAtla's lead product candidate, BA3011, is a conditionally active biologic designed to treat soft tissue and bone sarcomas, non-small cell lung cancer, and other tumors. The company is also advancing BA3021, targeting non-small cell lung cancer and melanoma, and BA3071, aimed at multiple cancer types including renal cell carcinoma and hepatocellular carcinoma. With over 150 patents and applications, BioAtla's innovative approach expands the potential for treating previously untreatable cancers and enhances the manufacturability of its drug candidates.

C Ray Therapeutics develops healthcare advancements through nuclear medicine. It was founded in 2020.

CardiaLen, Inc. is a medical device company based in Minneapolis, Minnesota, specializing in the development of innovative therapies for atrial fibrillation and other heart arrhythmias. Founded in 2008, the company is focused on creating implantable, low-energy cardioverter devices that offer pain-free cardioversion therapies. These devices monitor the heartbeat and employ a proprietary series of low-energy pulses to restore normal heart rhythm while minimizing discomfort and preventing damage to heart tissue. By addressing significant unmet needs in the treatment of atrial fibrillation, CardiaLen aims to enhance patient outcomes and reduce reliance on high-energy defibrillation shocks.

Swixx Biopharma fully represents biopharma companies in the CEE. It is designed to fully replace biopharma, OTC, and medical device multinationals’ subsidiaries or business units in those countries, or therapeutic areas of CEE, that the multinational chooses not to enter, or to exit. The company was founded in 2014 and is registered in Baar, Switzerland. It has 100%-owned affiliates in Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Greece, Hungary, Kosovo, Latvia, Lithuania, North Macedonia, Montenegro, Poland, Romania, Russia, Serbia, Slovakia, and Slovenia.

Sphingotec GmbH is a biomarker company based in Brandenburg, Germany, founded in 2002. The company specializes in developing and marketing in vitro diagnostic solutions that utilize novel blood-based protein biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions, including acute heart failure, acute kidney injury, and circulatory shock. Sphingotec also produces microtiter plates, which are commonly used in analytical research and diagnostic testing laboratories. Its focus is on addressing critically underserved diagnostic needs in the field of acute care, with an emphasis on improving patient outcomes through innovative biomarker technologies.

Mineralys Therapeutics is a biopharmaceutical company that provides hypertension treatment. They also bring a targeted approach to the management of hypertension.

Shape Memory Medical Inc, based in Santa Clara, California, is a medical device company focused on developing innovative therapeutic solutions for the peripheral vascular, cardiovascular, and neurovascular markets. Founded to commercialize cutting-edge medical devices that utilize Shape Memory Polymer (SMP) materials, the company has introduced the first FDA-cleared device employing this technology within the vascular sector. This advancement allows physicians to enhance patient care through improved treatment options. The team at Shape Memory Medical possesses significant expertise in SMP foam technology and the commercialization of medical devices, positioning the company as a leader in its field.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for the treatment of sepsis and related conditions. The company's lead product candidate, Adrecizumab, is a humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone that plays a critical role in maintaining vascular integrity. Adrenomed aims to rescue vascular integrity in critically ill patients facing limited treatment options, particularly those suffering from septic shock and acute heart failure. The company employs a unique approach that combines its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker for patient identification. Adrenomed has established a strong intellectual property position, holding granted patents in all major markets for its innovative therapies.

Monte Rosa Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics that utilize molecular glue degraders (MGDs) to modulate protein degradation pathways. By leveraging the body's natural mechanisms for protein destruction, these small molecule drugs selectively target and degrade disease-causing proteins. The company employs its QuEEN platform, which combines artificial intelligence and proprietary experimental tools, to identify relevant proteins for degradation. With a diverse library of over 50,000 MGD molecules, Monte Rosa's lead candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for treating MYC-driven tumors. The company aims to advance its pipeline of pioneering therapies for cancer and other diseases.

Valo Health is a technology company focused on transforming the drug discovery and development process through the integration of human and machine intelligence. By leveraging machine learning, cloud computing, and extensive data analysis, Valo Health's platform facilitates the identification of previously unknown connections between genetic markers and diseases. This human-centric approach supports clients in the healthcare sector in the development of treatments for various conditions, including oncology, neurodegenerative diseases, and cardiovascular issues. Through its innovative platform, Valo Health aims to accelerate the creation of impactful therapies.

Farmalisto is an online retailer that sells a range of products and services to its clients. The platform’s range of products include haircare, dampeners, solar protection, healing, moisturizing, anti-aging, toothbrushes, toothpastes, mouth rinses, dental silks, dentures, protection, cereals, baby hygiene, baby milks, and diapers. Farmalisto was launched in 2013 by Jose Mora Hernandez, Stefan Krautwald, and Matthias Fehr and is based in Bogota and Mexico City. Websites: https://www.farmalisto.com.mx https://www.farmalisto.com.co

Neuron23, Inc. is a biotechnology company focused on developing therapies for genetic disorders, particularly neurological diseases such as Parkinson's and Alzheimer's. Founded in 2018 and headquartered in South San Francisco, California, with an additional office in Munich, Germany, the company utilizes advanced artificial intelligence and genetic insights to enhance drug discovery. Neuron23's innovative platform integrates the latest advancements in human genetics with AI-driven methodologies to create targeted treatments for patients facing debilitating health challenges. By focusing on genetically defined conditions, Neuron23 aims to improve therapeutic options and outcomes for individuals affected by these disorders.

Nuance Biotech Inc. is a pharmaceutical development company based in Shanghai, China, founded in 2014. The company specializes in the research and development of various drug delivery methods, including capsules, injections, and tubes. In addition to its focus on drug development, Nuance Biotech offers a commercial and academic platform for pharmaceuticals and provides contract sales organization services to support its initiatives in the healthcare sector.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for the treatment of sepsis and related conditions. The company's lead product candidate, Adrecizumab, is a humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone that plays a critical role in maintaining vascular integrity. Adrenomed aims to rescue vascular integrity in critically ill patients facing limited treatment options, particularly those suffering from septic shock and acute heart failure. The company employs a unique approach that combines its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker for patient identification. Adrenomed has established a strong intellectual property position, holding granted patents in all major markets for its innovative therapies.

Swixx Biopharma fully represents biopharma companies in the CEE. It is designed to fully replace biopharma, OTC, and medical device multinationals’ subsidiaries or business units in those countries, or therapeutic areas of CEE, that the multinational chooses not to enter, or to exit. The company was founded in 2014 and is registered in Baar, Switzerland. It has 100%-owned affiliates in Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Greece, Hungary, Kosovo, Latvia, Lithuania, North Macedonia, Montenegro, Poland, Romania, Russia, Serbia, Slovakia, and Slovenia.

Everlife Asia is a buy-and-build platform aimed to provide complete solutions for the healthcare and research industries.

Ambrx, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, that specializes in the development of engineered precision biologics using an advanced genetic code technology platform. This innovative approach enables the incorporation of synthetic amino acids into proteins, leading to the creation of next-generation therapeutics, including antibody drug conjugates (ADCs), bispecific antibodies, and long-acting therapeutic peptides. Ambrx's development pipeline features several product candidates, such as ARX788, ARX517, and ARX305, which target various therapeutic areas, including oncology, metabolic, and cardiovascular diseases. The company collaborates with organizations like MabSpace Biosciences, BeiGene, and NovoCodex Biopharmaceuticals to enhance its research and development efforts. Founded in 2003, Ambrx aims to optimize the efficacy, safety, and usability of its biopharmaceutical products.

Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative medicines for neurological diseases. The company's proprietary pipeline includes several product candidates, notably LP352, a next-generation 5-HT2C agonist intended for treating developmental and epileptic encephalopathies. Additionally, Longboard is evaluating LP143, a full agonist of the cannabinoid type 2 receptor, which targets conditions such as amyotrophic lateral sclerosis and Parkinson's disease, as well as LP659, a selective modulator for multiple central nervous system neuroinflammatory disorders. Longboard Pharmaceuticals aims to optimize pharmacology and pharmacokinetics across its drug candidates, enhancing therapeutic outcomes for patients with rare neurological conditions. The company was incorporated in 2020 and was previously known as Arena Neuroscience, Inc.

Dren Bio is a biotechnology company that specializes in protein engineering technologies designed to target and deplete pathogenic cells, protein aggregates, and other disease-causing agents. With a focus on hematologic neoplasms, solid cancers, autoimmune disorders, and diseases related to protein aggregation, the company aims to provide innovative solutions for healthcare professionals in their efforts to combat various serious diseases. Operating under a holding company model, Dren Bio develops multiple projects as standalone assets, seeking to create value through its diverse portfolio of biotechnology initiatives.

BioShin Limited is a clinical-stage biopharmaceutical company based in Pudong, China, focused on developing innovative medicines and therapies for neurological, neuropsychiatric diseases, and rare disorders. Established in 2018, it operates as a wholly owned subsidiary of Biohaven Pharmaceuticals. The company specializes in late-stage product candidates and utilizes clinical trial platforms to explore treatments such as calcitonin gene-related peptide (CGRP) receptor antagonism for migraine and pain, glutamate modulation for Alzheimer’s disease and anxiety disorder, and myeloperoxidase (MPO) inhibition for inflammation and neurodegeneration. BioShin aims to address unmet medical needs in the neurological field, particularly within the Asia-Pacific market.

Galecto is a clinical-stage biotechnology company focused on developing small molecules to treat severe diseases, particularly fibrosis and cancer. The company’s lead product candidate, GB0139, is an inhaled inhibitor of galectin-3 aimed at addressing severe fibrotic lung diseases, including idiopathic pulmonary fibrosis, which presents a significant unmet medical need. Founded in 2011, Galecto builds upon more than a decade of research into the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic diseases. The company also develops additional therapeutics, such as GB1211, a selective oral galectin-3 inhibitor targeting fibrosis related to non-alcoholic steatohepatitis. Galecto's strong patent portfolio and research foundation position it uniquely within the therapeutic landscape for fibrosis and related diseases.

Monte Rosa Therapeutics is a biotechnology company focused on developing innovative cancer therapeutics that utilize molecular glue degraders (MGDs) to modulate protein degradation pathways. By leveraging the body's natural mechanisms for protein destruction, these small molecule drugs selectively target and degrade disease-causing proteins. The company employs its QuEEN platform, which combines artificial intelligence and proprietary experimental tools, to identify relevant proteins for degradation. With a diverse library of over 50,000 MGD molecules, Monte Rosa's lead candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for treating MYC-driven tumors. The company aims to advance its pipeline of pioneering therapies for cancer and other diseases.

Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.

Sphingotec GmbH is a biomarker company based in Brandenburg, Germany, founded in 2002. The company specializes in developing and marketing in vitro diagnostic solutions that utilize novel blood-based protein biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions, including acute heart failure, acute kidney injury, and circulatory shock. Sphingotec also produces microtiter plates, which are commonly used in analytical research and diagnostic testing laboratories. Its focus is on addressing critically underserved diagnostic needs in the field of acute care, with an emphasis on improving patient outcomes through innovative biomarker technologies.

BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing specific and selective antibody-based therapeutics for various cancers. The company employs a proprietary platform to create conditionally active biologics (CABs), which enhance targeting of cancerous tissues while minimizing effects on normal cells, thereby improving safety and efficacy. BioAtla's lead product candidate, BA3011, is a conditionally active biologic designed to treat soft tissue and bone sarcomas, non-small cell lung cancer, and other tumors. The company is also advancing BA3021, targeting non-small cell lung cancer and melanoma, and BA3071, aimed at multiple cancer types including renal cell carcinoma and hepatocellular carcinoma. With over 150 patents and applications, BioAtla's innovative approach expands the potential for treating previously untreatable cancers and enhances the manufacturability of its drug candidates.

1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, that aims to make healthcare more accessible, understandable, and affordable. Launched in 2015, it allows users to find detailed information about medicines prescribed by doctors and purchase them directly. The platform enables users to search for drugs based on ailments, classes, companies, and brands. Additionally, 1mg offers a service that helps consumers find the right healthcare professionals tailored to their needs. Its diagnostics service enhances transparency and cost-effectiveness in lab tests, empowering Indian consumers and caregivers to choose appropriate healthcare services at competitive prices.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for the treatment of sepsis and related conditions. The company's lead product candidate, Adrecizumab, is a humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone that plays a critical role in maintaining vascular integrity. Adrenomed aims to rescue vascular integrity in critically ill patients facing limited treatment options, particularly those suffering from septic shock and acute heart failure. The company employs a unique approach that combines its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker for patient identification. Adrenomed has established a strong intellectual property position, holding granted patents in all major markets for its innovative therapies.

Guangdong Jianke Pharmaceutical Co., Ltd. operates a network of nine pharmacy stores and an online retail platform in China. Established in 2006 and based in Dongguan, the company offers a diverse range of products, including medications for hepatobiliary, dermatology, pediatric, and urology conditions, as well as treatments for digestive, nervous, and respiratory systems. Jianke also provides female health medication, health care products, medical instruments, and beauty care items. The company focuses on addressing the needs of patients with chronic diseases through its online chronic disease management services, which complement its pharmacy offerings. Its primary revenue stream comes from online retail pharmacy services, supplemented by comprehensive medical services and tailored marketing solutions.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for the treatment of sepsis and related conditions. The company's lead product candidate, Adrecizumab, is a humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone that plays a critical role in maintaining vascular integrity. Adrenomed aims to rescue vascular integrity in critically ill patients facing limited treatment options, particularly those suffering from septic shock and acute heart failure. The company employs a unique approach that combines its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker for patient identification. Adrenomed has established a strong intellectual property position, holding granted patents in all major markets for its innovative therapies.

Shape Memory Medical Inc, based in Santa Clara, California, is a medical device company focused on developing innovative therapeutic solutions for the peripheral vascular, cardiovascular, and neurovascular markets. Founded to commercialize cutting-edge medical devices that utilize Shape Memory Polymer (SMP) materials, the company has introduced the first FDA-cleared device employing this technology within the vascular sector. This advancement allows physicians to enhance patient care through improved treatment options. The team at Shape Memory Medical possesses significant expertise in SMP foam technology and the commercialization of medical devices, positioning the company as a leader in its field.

Farmalisto is an online retailer that sells a range of products and services to its clients. The platform’s range of products include haircare, dampeners, solar protection, healing, moisturizing, anti-aging, toothbrushes, toothpastes, mouth rinses, dental silks, dentures, protection, cereals, baby hygiene, baby milks, and diapers. Farmalisto was launched in 2013 by Jose Mora Hernandez, Stefan Krautwald, and Matthias Fehr and is based in Bogota and Mexico City. Websites: https://www.farmalisto.com.mx https://www.farmalisto.com.co

Swixx Biopharma fully represents biopharma companies in the CEE. It is designed to fully replace biopharma, OTC, and medical device multinationals’ subsidiaries or business units in those countries, or therapeutic areas of CEE, that the multinational chooses not to enter, or to exit. The company was founded in 2014 and is registered in Baar, Switzerland. It has 100%-owned affiliates in Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Greece, Hungary, Kosovo, Latvia, Lithuania, North Macedonia, Montenegro, Poland, Romania, Russia, Serbia, Slovakia, and Slovenia.

Farmalisto is an online retailer that sells a range of products and services to its clients. The platform’s range of products include haircare, dampeners, solar protection, healing, moisturizing, anti-aging, toothbrushes, toothpastes, mouth rinses, dental silks, dentures, protection, cereals, baby hygiene, baby milks, and diapers. Farmalisto was launched in 2013 by Jose Mora Hernandez, Stefan Krautwald, and Matthias Fehr and is based in Bogota and Mexico City. Websites: https://www.farmalisto.com.mx https://www.farmalisto.com.co

Harmony Biosciences is a commercial-stage pharmaceutical company based in Plymouth Meeting, Pennsylvania, founded in 2017. The company is dedicated to developing and commercializing innovative therapies for patients with rare neurological disorders who have unmet medical needs. Its primary product, WAKIX (pitolisant), is designed to treat narcolepsy in pediatric patients and has a unique mechanism of action that enhances histamine signaling in the brain by binding to H3 receptors. Harmony Biosciences aims to address critical therapeutic gaps in the treatment of neurological conditions, focusing on improving the quality of life for affected individuals.

MicroOptx is an early-stage medical device company that leverages academic bioengineering, surgical expertise, microengineering manufacturing, and nanotechnology to provide the modern solution for the vexing problem of Glaucoma. It develops a platform technology to shunt aqueous humor from the anterior chamber to the surface of the eye. The company is driven by a mission is to change the way the world treats glaucoma: and to halt the devastating effects of this progressive disease. MicroOptx is led by recognized medical, industry and financial veterans who are dedicated to preventing blindness.

1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, that aims to make healthcare more accessible, understandable, and affordable. Launched in 2015, it allows users to find detailed information about medicines prescribed by doctors and purchase them directly. The platform enables users to search for drugs based on ailments, classes, companies, and brands. Additionally, 1mg offers a service that helps consumers find the right healthcare professionals tailored to their needs. Its diagnostics service enhances transparency and cost-effectiveness in lab tests, empowering Indian consumers and caregivers to choose appropriate healthcare services at competitive prices.

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing medicines for underserved patient populations affected by rare diseases and cancer. The company employs a precision medicine approach and has a diverse portfolio of small molecule targeted oncology products. Its lead candidate, nirogacestat, an oral gamma secretase inhibitor, is currently in Phase III clinical trials for desmoid tumors. Additionally, SpringWorks is advancing several other product candidates, including mirdametinib, an oral MEK inhibitor in Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas, and various combinations involving nirogacestat for multiple myeloma. The company has established collaborations with organizations such as BeiGene, GlaxoSmithKline, and Allogene, aimed at enhancing the development of its therapies. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks is committed to unlocking the potential of its pipeline to provide innovative solutions for patients suffering from cancer and rare diseases.

Nuance Biotech Inc. is a pharmaceutical development company based in Shanghai, China, founded in 2014. The company specializes in the research and development of various drug delivery methods, including capsules, injections, and tubes. In addition to its focus on drug development, Nuance Biotech offers a commercial and academic platform for pharmaceuticals and provides contract sales organization services to support its initiatives in the healthcare sector.

Adrenomed AG is a clinical-stage biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for the treatment of sepsis and related conditions. The company's lead product candidate, Adrecizumab, is a humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone that plays a critical role in maintaining vascular integrity. Adrenomed aims to rescue vascular integrity in critically ill patients facing limited treatment options, particularly those suffering from septic shock and acute heart failure. The company employs a unique approach that combines its therapeutic antibody with a specific diagnostic tool that utilizes Adrenomedullin as a biomarker for patient identification. Adrenomed has established a strong intellectual property position, holding granted patents in all major markets for its innovative therapies.

Galecto is a clinical-stage biotechnology company focused on developing small molecules to treat severe diseases, particularly fibrosis and cancer. The company’s lead product candidate, GB0139, is an inhaled inhibitor of galectin-3 aimed at addressing severe fibrotic lung diseases, including idiopathic pulmonary fibrosis, which presents a significant unmet medical need. Founded in 2011, Galecto builds upon more than a decade of research into the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic diseases. The company also develops additional therapeutics, such as GB1211, a selective oral galectin-3 inhibitor targeting fibrosis related to non-alcoholic steatohepatitis. Galecto's strong patent portfolio and research foundation position it uniquely within the therapeutic landscape for fibrosis and related diseases.

CardiaLen, Inc. is a medical device company based in Minneapolis, Minnesota, specializing in the development of innovative therapies for atrial fibrillation and other heart arrhythmias. Founded in 2008, the company is focused on creating implantable, low-energy cardioverter devices that offer pain-free cardioversion therapies. These devices monitor the heartbeat and employ a proprietary series of low-energy pulses to restore normal heart rhythm while minimizing discomfort and preventing damage to heart tissue. By addressing significant unmet needs in the treatment of atrial fibrillation, CardiaLen aims to enhance patient outcomes and reduce reliance on high-energy defibrillation shocks.

Sphingotec GmbH is a biomarker company based in Brandenburg, Germany, founded in 2002. The company specializes in developing and marketing in vitro diagnostic solutions that utilize novel blood-based protein biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions, including acute heart failure, acute kidney injury, and circulatory shock. Sphingotec also produces microtiter plates, which are commonly used in analytical research and diagnostic testing laboratories. Its focus is on addressing critically underserved diagnostic needs in the field of acute care, with an emphasis on improving patient outcomes through innovative biomarker technologies.

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, dedicated to developing innovative therapies that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic currently undergoing Phase III clinical trials for the treatment of severe oral mucositis induced by radiation in patients with head and neck cancer. Additionally, it is being tested in Phase IIa trials for radiotherapy-induced esophagitis in lung cancer patients. Galera is also advancing a second candidate, GC4711, which is in Phase I/II trials targeting pancreatic and lung cancers. The company was founded in 2012 and is committed to addressing severe side effects associated with cancer treatments to improve patient outcomes.

Guangdong Jianke Pharmaceutical Co., Ltd. operates a network of nine pharmacy stores and an online retail platform in China. Established in 2006 and based in Dongguan, the company offers a diverse range of products, including medications for hepatobiliary, dermatology, pediatric, and urology conditions, as well as treatments for digestive, nervous, and respiratory systems. Jianke also provides female health medication, health care products, medical instruments, and beauty care items. The company focuses on addressing the needs of patients with chronic diseases through its online chronic disease management services, which complement its pharmacy offerings. Its primary revenue stream comes from online retail pharmacy services, supplemented by comprehensive medical services and tailored marketing solutions.

YmAbs is a clinical stage biopharmaceutical company that discovers and develops innovative treatments for cancer patients through immunotherapies. YmAbs utilizes its platform technologies to create next-generation humanized, affinity matured bispecific antibodies. To further improve its bispecific antibodies, the company collaborates on the development of a novel human protein tag that dimerizes T-cell engaging bispecific antibodies, which enables higher tumor binding and results in a longer serum half-life and a significantly greater T-cell mediated killing of tumor cells. YmAbs' treatments claims to potentially reduce longer-term toxicities associated with current chemotherapeutics and provide the potential for curative therapy even for patients with widespread disease. YmAbs’ goal is to drive multiple product candidates in select solid tumor cancers to FDA approval.

YmAbs is a clinical stage biopharmaceutical company that discovers and develops innovative treatments for cancer patients through immunotherapies. YmAbs utilizes its platform technologies to create next-generation humanized, affinity matured bispecific antibodies. To further improve its bispecific antibodies, the company collaborates on the development of a novel human protein tag that dimerizes T-cell engaging bispecific antibodies, which enables higher tumor binding and results in a longer serum half-life and a significantly greater T-cell mediated killing of tumor cells. YmAbs' treatments claims to potentially reduce longer-term toxicities associated with current chemotherapeutics and provide the potential for curative therapy even for patients with widespread disease. YmAbs’ goal is to drive multiple product candidates in select solid tumor cancers to FDA approval.

Harmony Biosciences is a commercial-stage pharmaceutical company based in Plymouth Meeting, Pennsylvania, founded in 2017. The company is dedicated to developing and commercializing innovative therapies for patients with rare neurological disorders who have unmet medical needs. Its primary product, WAKIX (pitolisant), is designed to treat narcolepsy in pediatric patients and has a unique mechanism of action that enhances histamine signaling in the brain by binding to H3 receptors. Harmony Biosciences aims to address critical therapeutic gaps in the treatment of neurological conditions, focusing on improving the quality of life for affected individuals.

Shape Memory Medical Inc, based in Santa Clara, California, is a medical device company focused on developing innovative therapeutic solutions for the peripheral vascular, cardiovascular, and neurovascular markets. Founded to commercialize cutting-edge medical devices that utilize Shape Memory Polymer (SMP) materials, the company has introduced the first FDA-cleared device employing this technology within the vascular sector. This advancement allows physicians to enhance patient care through improved treatment options. The team at Shape Memory Medical possesses significant expertise in SMP foam technology and the commercialization of medical devices, positioning the company as a leader in its field.

1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, that aims to make healthcare more accessible, understandable, and affordable. Launched in 2015, it allows users to find detailed information about medicines prescribed by doctors and purchase them directly. The platform enables users to search for drugs based on ailments, classes, companies, and brands. Additionally, 1mg offers a service that helps consumers find the right healthcare professionals tailored to their needs. Its diagnostics service enhances transparency and cost-effectiveness in lab tests, empowering Indian consumers and caregivers to choose appropriate healthcare services at competitive prices.

Complexa, Inc. is a biopharmaceutical company based in Berwyn, Pennsylvania, focused on developing treatments for severe and life-threatening diseases related to fibrosis and inflammation. Established in 2008, the company is advancing its lead compound, CXA-10, an oral nitrated fatty acid aimed at treating focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH). Complexa utilizes proprietary technologies that involve the synthesis of endogenous nitro-fatty acids, which serve as cell-signaling agents regulating key inflammatory pathways. This approach aims to enhance the body's natural mechanisms for resolving and repairing acute and chronic tissue injuries, with a focus on addressing various inflammatory, fibrotic, and central nervous system diseases.

Amphora Medical, Inc. is a Minnesota-based company that develops medical devices aimed at treating female overactive bladder (OAB) syndrome. Founded in 2011 and headquartered in Maple Grove, Minnesota, the company is focused on creating a novel cystoscopic device designed to enhance bladder function and improve the quality of life for individuals suffering from this condition. Utilizing minimally invasive procedures, Amphora Medical's innovative technology has the potential to offer significant benefits to patients dealing with OAB.

1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, that aims to make healthcare more accessible, understandable, and affordable. Launched in 2015, it allows users to find detailed information about medicines prescribed by doctors and purchase them directly. The platform enables users to search for drugs based on ailments, classes, companies, and brands. Additionally, 1mg offers a service that helps consumers find the right healthcare professionals tailored to their needs. Its diagnostics service enhances transparency and cost-effectiveness in lab tests, empowering Indian consumers and caregivers to choose appropriate healthcare services at competitive prices.

Amicus is dedicated to service of research-based pharmaceutical and healthcare companies who choose to enter the Balkans and the Baltics in partnership, and not entirely with their own subsidiaries. The company is staffed by a unique group of skilled managers and medical professionals who are dedicated to bring modern medicines to the people of our two regions. We are a service-oriented, high quality and ethically-driven company.

True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company’s lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, kidney transplant, dermatology, and neurological space. True North was formed in 2013 as a spin-out of iPierian.

Vitaeris has licensed global exclusive rights to the best-in-class anti-interleukin-6 monoclonal antibody Clazakizumab from Alder Biopharmaceuticals, and is actively pursuing innovative applications in chronic inflammatory diseases.

1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, that aims to make healthcare more accessible, understandable, and affordable. Launched in 2015, it allows users to find detailed information about medicines prescribed by doctors and purchase them directly. The platform enables users to search for drugs based on ailments, classes, companies, and brands. Additionally, 1mg offers a service that helps consumers find the right healthcare professionals tailored to their needs. Its diagnostics service enhances transparency and cost-effectiveness in lab tests, empowering Indian consumers and caregivers to choose appropriate healthcare services at competitive prices.

1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, that aims to make healthcare more accessible, understandable, and affordable. Launched in 2015, it allows users to find detailed information about medicines prescribed by doctors and purchase them directly. The platform enables users to search for drugs based on ailments, classes, companies, and brands. Additionally, 1mg offers a service that helps consumers find the right healthcare professionals tailored to their needs. Its diagnostics service enhances transparency and cost-effectiveness in lab tests, empowering Indian consumers and caregivers to choose appropriate healthcare services at competitive prices.

ObsEva SA is a Swiss-based, speciality biopharmaceutical company dedicated to the development of innovative drugs for women's reproductive medicine. ObsEva's main focus is on therapies for preterm labor. ObsEva was founded in November 2012, by Ernest Loumaye MD, PhD and André Chollet PhD. Ernest Loumaye is a specialist in female reproductive medicine with 20 years of experience in the biopharmaceutical industry. Ernest Loumaye was previously Co-Founder and CEO of PregLem SA, a successful biopharmaceutical company which was acquired by Gedeon Richter in 2010. André Chollet is specialist in medicinal and pharmaceutical chemistry with more than 30 years of experience in diverse positions in the biopharmaceutical industry, including in Biogen, GSK and Merck Serono. André Chollet was responsible for the preterm labor program at Serono before the acquisition of the company by Merck KGaA.

AnaptysBio is a privately-held therapeutic antibody product company that uses of somatic hypermutation, or SHM, for antibody discovery and optimization. SHM is the body's natural process for generating potent antibodies to fight disease. The Company's SHM-Platform utilizes the key components of SHM and other techniques to generate antibodies for therapeutic applications through an iterative process of natural evolution and high-throughput selection a process that has been referred to as naturalizing antibodies. This versatile platform can be used both to discover and optimize antibodies directed at specific disease targets and also affinity mature existing antibodies to improve their binding properties. In addition to providing a more powerful approach to antibody discovery and protein optimization, it addresses a growing void in the therapeutic antibody field due to a string of acquisitions and licensing deals that have reduced the availability of many technologies.

Autonomic Technologies, Inc. is a medical device company that specializes in developing and commercializing innovative therapies for autonomic disorders, with a particular emphasis on severe headaches. Founded in 2007 and headquartered in Mountain View, California, the company has additional offices in Germany and Switzerland. Its flagship product, the ATI Neurostimulation System, is a miniaturized, battery-less microstimulator designed to deliver low-level energy directly to the sphenopalatine ganglion (SPG) to effectively treat chronic cluster headaches. This technology aims to set a new standard in the management of severe headaches and migraines, providing patients with a safe and effective treatment option.

Kolltan Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the discovery and development of monoclonal antibody drugs that target receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. Founded in 2007 and based in New Haven, Connecticut, Kolltan's lead product candidate, KTN3379, is an antibody targeting the ErbB3 RTK and is currently undergoing Phase I clinical trials for adult patients with advanced solid tumors. The company is also advancing KTN0158, a KIT RTK inhibitor aimed at treating neurofibromatosis type 1 and other inflammatory diseases, as well as KIT-ADC, an antibody-drug conjugate for oncology. Kolltan's research is informed by groundbreaking work in the laboratory of Dr. Joseph Schlessinger, which elucidates the molecular mechanisms of RTK activation and its implications for cancer.

Advanced Accelerator Applications S.A. specializes in the development, production, and commercialization of molecular nuclear diagnostic and therapeutic medicine products. The company offers a range of radioligand therapies and precision imaging radioligands, primarily targeting oncology, cardiology, and neurology. Its product portfolio includes oxodotreotide, dotatate injections, and various solutions aimed at reducing radiation exposure during treatments. Advanced Accelerator Applications also provides a theragnostic platform that facilitates diagnosis, monitoring, and staging of tumors by using radiolabeled targeting molecules. Founded in 2002 and headquartered in Saint Genis Pouilly, France, the company operates as a subsidiary of Novartis AG.

PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for the treatment of rare disorders and cancer. The company offers Translarna, used for nonsense mutation Duchenne muscular dystrophy in ambulatory patients, and Emflaza, a corticosteroid for the same condition. PTC Therapeutics is advancing several candidates in clinical development, including Translarna for other rare genetic conditions, RG7916 and RO7034067 for spinal muscular atrophy, and PTC596 and PTC299, which target cancer through dihydrooratate dehydrogenase inhibition. Additionally, the company is developing a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics collaborates with various organizations, including F. Hoffman-La Roche Ltd and Massachusetts General Hospital, to further its research and commercialization efforts. Founded in 1998, the company is headquartered in South Plainfield, New Jersey.

Kolltan Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the discovery and development of monoclonal antibody drugs that target receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. Founded in 2007 and based in New Haven, Connecticut, Kolltan's lead product candidate, KTN3379, is an antibody targeting the ErbB3 RTK and is currently undergoing Phase I clinical trials for adult patients with advanced solid tumors. The company is also advancing KTN0158, a KIT RTK inhibitor aimed at treating neurofibromatosis type 1 and other inflammatory diseases, as well as KIT-ADC, an antibody-drug conjugate for oncology. Kolltan's research is informed by groundbreaking work in the laboratory of Dr. Joseph Schlessinger, which elucidates the molecular mechanisms of RTK activation and its implications for cancer.

Ellipse Technologies is a privately-held medical device company based in California, specializing in the development of innovative implantable remote control technology for spinal and orthopedic applications. The company focuses on creating non-invasively adjustable implants designed to address a wide range of conditions, including spinal deformities and orthopedic trauma. Its flagship products include the MAGEC MAGnetic Expansion Control System, which employs a minimally-invasive method to correct spinal deformities through remote adjustment using an external magnetic field, and the PRECICE System, which utilizes adjustable intramedullary rods or bone plates to manage long-bone abnormalities resulting from fractures. Ellipse is dedicated to advancing treatment options in the fields of spinal and orthopedic medicine.

Vivacta Limited, a Sittingbourne, UK-based medical diagnostics company that develops an innovative platform for point of care testing. Vivacta’s innovative piezofilm technology platform enables the advancement of new near‐patient diagnostic products. The company has successfully developed a test for thyroid stimulating hormone (TSH), and is working on a multiple analyte cardiovascular diagnostic test for use in the emergency room and acute care settings, where there is a need for rapid diagnosis of possible heart attack and related time‐critical medical conditions.

Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.

PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of orally administered small-molecule therapeutics for the treatment of rare disorders and cancer. The company offers Translarna, used for nonsense mutation Duchenne muscular dystrophy in ambulatory patients, and Emflaza, a corticosteroid for the same condition. PTC Therapeutics is advancing several candidates in clinical development, including Translarna for other rare genetic conditions, RG7916 and RO7034067 for spinal muscular atrophy, and PTC596 and PTC299, which target cancer through dihydrooratate dehydrogenase inhibition. Additionally, the company is developing a gene therapy candidate, PTC-AADC, for Aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics collaborates with various organizations, including F. Hoffman-La Roche Ltd and Massachusetts General Hospital, to further its research and commercialization efforts. Founded in 1998, the company is headquartered in South Plainfield, New Jersey.

IVERIC bio is a biopharmaceutical company dedicated to discovering and developing innovative treatment options for retinal diseases that have significant unmet medical needs. The company is actively working on therapeutic product candidates aimed at age-related retinal diseases, as well as gene therapy product candidates designed for orphan inherited retinal diseases. Through its focused research and development efforts, IVERIC bio seeks to address critical gaps in the treatment landscape for patients suffering from these conditions.

Kolltan Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the discovery and development of monoclonal antibody drugs that target receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. Founded in 2007 and based in New Haven, Connecticut, Kolltan's lead product candidate, KTN3379, is an antibody targeting the ErbB3 RTK and is currently undergoing Phase I clinical trials for adult patients with advanced solid tumors. The company is also advancing KTN0158, a KIT RTK inhibitor aimed at treating neurofibromatosis type 1 and other inflammatory diseases, as well as KIT-ADC, an antibody-drug conjugate for oncology. Kolltan's research is informed by groundbreaking work in the laboratory of Dr. Joseph Schlessinger, which elucidates the molecular mechanisms of RTK activation and its implications for cancer.

Vivacta Limited, a Sittingbourne, UK-based medical diagnostics company that develops an innovative platform for point of care testing. Vivacta’s innovative piezofilm technology platform enables the advancement of new near‐patient diagnostic products. The company has successfully developed a test for thyroid stimulating hormone (TSH), and is working on a multiple analyte cardiovascular diagnostic test for use in the emergency room and acute care settings, where there is a need for rapid diagnosis of possible heart attack and related time‐critical medical conditions.

Mpex Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies to address the critical problem of antibiotic resistance, particularly concerning gram-negative bacteria. The company's internal development pipeline emphasizes the combination of proprietary formulations, pharmacokinetics/pharmacodynamics strategies, and novel potentiating agents with established antibiotics. This approach aims to counteract or inhibit the molecular mechanisms that contribute to antibiotic resistance. One of its key products, MP-376, is a proprietary formulation of levofloxacin designed as a maintenance therapy to prevent bacterial exacerbations in patients with cystic fibrosis and chronic obstructive pulmonary disease. Through these efforts, Mpex Pharmaceuticals seeks to provide effective solutions in the fight against resistant bacterial infections.

Broncus Medical is a medical technology company specializing in the development of minimally-invasive devices for treating lung diseases, particularly emphysema. The company is known for its Exhale product line, which features the patented Airway Bypass technique, potentially being the first minimally-invasive procedure for homogeneous emphysema, a common form of the disease affecting many patients. Broncus is actively enrolling participants in its pivotal EASE Trial to evaluate this innovative treatment for severe homogeneous emphysema. In addition to its emphysema-focused efforts, Broncus operates within the interventional pulmonology sector, offering a range of products designed to enhance the diagnosis and treatment of lung conditions, including lung cancer and chronic obstructive pulmonary disease (COPD). The company is headquartered in Mountain View, California, with an international presence in Nyon, Switzerland.

Kolltan Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the discovery and development of monoclonal antibody drugs that target receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. Founded in 2007 and based in New Haven, Connecticut, Kolltan's lead product candidate, KTN3379, is an antibody targeting the ErbB3 RTK and is currently undergoing Phase I clinical trials for adult patients with advanced solid tumors. The company is also advancing KTN0158, a KIT RTK inhibitor aimed at treating neurofibromatosis type 1 and other inflammatory diseases, as well as KIT-ADC, an antibody-drug conjugate for oncology. Kolltan's research is informed by groundbreaking work in the laboratory of Dr. Joseph Schlessinger, which elucidates the molecular mechanisms of RTK activation and its implications for cancer.